Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.
10.1016/S1875-5364(22)60144-4
- Author:
Li-Hui ZHANG
1
;
Wan-Ying ZHANG
1
;
Jia-Ming XIONG
1
;
Xiu-Mei DUAN
2
;
Li-Na HAI
3
,
4
;
Yu-Liang ZHANG
1
;
Miao-Miao ZHANG
1
;
Gui-Fang QIN
1
;
Guo-Wei ZHANG
5
Author Information
1. College of Traditional Chinese Medicine, Hebei University, Baoding 071002, China.
2. Beijing Zhendong Guangming Pharmaceutical Research Institute, Beijing 100085, China.
3. Beijing Zhendong Guangming Pharmaceutical Research Institute, Beijing 100085, China
4. Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
5. College of Traditional Chinese Medicine, Hebei University, Baoding 071002, China. Electronic address: xxzgw@126.com.
- Publication Type:Journal Article
- Keywords:
Bladder cancer;
Compound Kushen Injection;
GEO;
Molecular mechanism;
Network pharmacology
- MeSH:
Computational Biology;
Drugs, Chinese Herbal;
Humans;
Network Pharmacology;
Phosphatidylinositol 3-Kinases;
Urinary Bladder Neoplasms/genetics*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(1):43-53
- CountryChina
- Language:English
-
Abstract:
Bladder cancer is the most common malignancy of the urinary system. Compound Kushen Injection (CKI) is a Chinese medicinal preparation that has been widely used in the treatment of various types of cancers in the past two decades. However, the pharmacological effect of CKI on bladder cancer is not still completely understood. In the current study, network pharmacology combined with bioinformatics was used to elucidate the therapeutic mechanism and potential targets of CKI in bladder cancer. The mechanism by which CKI was effective against bladder cancer was further verified in vitro using human bladder cancer cell line T24. Network pharmacology analysis identified 35 active compounds and 268 target genes of CKI. Bioinformatics data indicated 5500 differentially expressed genes associated with bladder cancer. Common genes of CKI and bladder cancer suggested that CKI exerted anti-bladder cancer effects by regulating genes such as MMP-9, JUN, EGFR, and ERK1. Functional enrichment analysis indicated that CKI exerted therapeutic effects on bladder cancer by regulating certain biological processes, including cell proliferation, cell migration, and cell apoptosis. In addition, Kyoto Encyclopedia of Genes and Genomes enrichment analysis implicated pathways related to cancer, bladder cancer, and the PI3K-Akt signaling pathway. Consistently, cell experiments indicated that CKI inhibited the proliferation and migration of T24 cells, and induced their apoptosis. Moreover, RT-qPCR and Western blot results demonstrated that CKI was likely to treat bladder cancer by down-regulating the gene and protein expression of MMP-9, JUN, EGFR, and ERK1. CKI inhibited the proliferation and migration, and induced the apoptosis of T24 bladder cancer cells through multiple biological pathways and targets. CKI also exhibited significant effects on the regulation of key genes and proteins associated with bladder cancer. Overall, our findings provide solid evidence and deepen current understanding of the therapeutic effects of CKI for bladder cancer, and further support its clinical use.
